Filing Flows › Keros Therapeutics (KROS) › How it makes money
How Keros Therapeutics (KROS) makes money
Keros Therapeutics (KROS) made $40.0M of revenue in the third quarter 2026 (Q3 2026), +183% from a year earlier. Of every dollar of revenue, 32¢ was left as operating profit, 35¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $40.0M | 100.0% |
| Operating profit | $12.8M | 32.0% |
| Income tax | $772K | 1.9% |
| Net earnings | $14.2M | 35.4% |
| Operating cash flow | $3.4M | 8.5% |
| Free cash flow | $3.3M | 8.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $40.0M | +183% |
| Q1 2026 | $367K | -100% |
| Q4 2025 | $380K | -88% |
| Q3 2025 | $14.1M | 36× |
| Q2 2025 | $18.2M | 491× |
| Q1 2025 | $211M | 2,544× |
From Keros Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Keros Therapeutics make money?
Keros Therapeutics (KROS) made $40.0M of revenue in the third quarter 2026 (Q3 2026), +183% from a year earlier. Of every dollar of revenue, 32¢ was left as operating profit, 35¢ was left as net earnings.
What is Keros Therapeutics' profit margin?
Net earnings were $14.2M, 35.4% of revenue, in the third quarter 2026; the operating margin was 32.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.